Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.
İlgili Semboller 1
HALO HALO
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.